Afm13 clinical trial
WebMay 13, 2024 · These results led to the launch of a Phase I clinical trial to evaluate the combination of cord blood-derived NK cells (cbNK cells) with AFM13 as an experimental cell-based immunotherapy in ... WebApr 10, 2024 · Affimed’s AFM13 is a proprietary bispecific antibody designed to bind to CD16A on NK cells and CD30 on lymphoma cells, allowing NK cells to eliminate cancer …
Afm13 clinical trial
Did you know?
WebJul 1, 2024 · Immune cell engagers have been developed to overcome barriers related to deficient cancer recognition and NK-cell activation. AFM13 is a tetravalent bispecific … WebJan 28, 2016 · Brief Summary: The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy. Condition or disease.
WebAug 1, 2015 · Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK … WebHeidelberg, Germany, April 10, 2024 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided a data update from the ongoing study of the Company’s lead innate cell engager (ICE®) AFM13 precomplexed with cord blood …
WebDec 22, 2014 · GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma (GHSG-AFM13) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. WebApr 10, 2024 · The antibody, innate cell engager AFM13, acts as a bridge between the two cell types, helping the natural killer cells more effectively fight the cancer. Prior studies with AFM13 showed preliminary efficacy in clinical trials of patients with Hodgkin lymphoma, T-cell lymphoma, and peripheral T-cell lymphoma.
WebNov 19, 2024 · Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase 1b study was registered at www.clinicaltrials.gov as NCT02665650 . © 2024 by The American Society …
WebApr 14, 2024 · American Association for Cancer Research (AACR) 2024 Preview – Top Data Readouts. The upcoming AACR 2024 Annual Meeting will have a range of abstracts, including regular abstracts, clinical trials, and late-breaking abstracts. Among the abstracts being presented at the conference, we have listed a few potential abstracts, which we … bsg game cheat sheetWebTo assess the efficacy of the bispecific anti-CD30/CD16A, NK-cell engaging antibody AFM13 and to select the optimal treatment schedule (arm A-C), we initiated a randomized two-stage phase II trial ( NCT02321592 ). Due to slow recruitment, the trial was terminated after treatment of 25 patients. exception getting adyen paymentWebJun 25, 2015 · CLINICAL TRIALS AND OBSERVATIONS June 25, 2015 A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma Clinical Trials & Observations Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus … exception handler tableWebDec 10, 2024 · December 10, 2024, 2:20 PM · 9 min read Affimed N.V. AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin... exception handler springWebSearch clinical trials for: AFM13 . Total 5 results. NCT04074746. Recruiting. Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas. bsg gastric cancer guidelinesWebMar 23, 2024 · AFM13 (CD30/CD16A) In January 2024, Affimed received feedback from the Food and Drug Administration (FDA) to its pre-investigational new drug (IND) meeting request in support of a planned... exception handling and text i/oWebAFM13 is Affimed’s most advanced ICE® clinical program and is currently being evaluated as a monotherapy in a registration-directed trial in patients with relapsed/refractory peripheral T-cell lymphoma or transformed mycosis fungoides (REDIRECT). ... Our data is the perfect blend of ~600,000 clinical trials from over the last 20 years ... exception handling annotation in java